PROLONGATION OF DISEASE-FREE AND OVERALL SURVIVAL WITH THE ADJUVANT FAC-BCG IN STAGE-II, STAGE-III BREAST-CANCER

被引：0
|
作者：
BUZDAR, AU [1 ]
BLUMENSCHEIN, GR [1 ]
GUTTERMAN, JU [1 ]
TASHIMA, CK [1 ]
HORTOBAGYI, GN [1 ]
SMITH, TL [1 ]
HERSH, EM [1 ]
FREIREICH, EJ [1 ]
GEHAN, EA [1 ]
机构：
[1] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,HOUSTON,TX 77030
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1979年 / 20卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 352
页数：1
相关论文
共 50 条
  • [31] POSTOPERATIVE ADJUVANT CHEMOTHERAPY OF STAGE-II BREAST-CANCER IN POSTMENOPAUSAL WOMEN
    NORTON, L
    [J]. CANCER INVESTIGATION, 1986, 4 (05) : 498 - 499
  • [32] ADJUVANT TAMOXIFEN IN POSTMENOPAUSAL STAGE-II BREAST-CANCER 5 YEARS ON
    MIKL, J
    CZERWENKA, K
    SALZER, H
    SPONA, J
    AIGINGER, P
    KUBISTA, E
    SEVELDA, P
    STAFFEN, A
    ZIELINSKI, CC
    [J]. LANCET, 1990, 335 (8688): : 541 - 541
  • [33] ADJUVANT CHEMOTHERAPY FOR POOR PROGNOSIS ESTROGEN-RECEPTOR NEGATIVE STAGE-II STAGE-III BREAST-CANCER ONE YEAR VS 2 YRS CMFVP
    RIVKIN, S
    GREEN, S
    METCH, B
    OSBORNE, CK
    KNIGHT, WA
    MCDIVITT, R
    CRUZ, A
    TESH, D
    COSTANZI, J
    BALCERZAK, S
    STEVENS, R
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (01) : 147 - 147
  • [34] ADJUVANT CHEMOTHERAPY FOR POOR PROGNOSIS ESTROGEN-RECEPTOR NEGATIVE STAGE-II, STAGE-III BREAST-CANCER ONE YEAR VS 2 YRS CMFVP
    RIVKIN, S
    GREEN, S
    METCH, B
    OSBORNE, CK
    KNIGHT, WA
    MCDIVITT, R
    CRUZ, A
    TESH, D
    COSTANZI, J
    BALCERZAK, S
    STEVENS, R
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1986, 8 (01) : 80 - 80
  • [35] SELECTION OF THERAPY FOR STAGE-III BREAST-CANCER
    SWAIN, SM
    [J]. SURGICAL CLINICS OF NORTH AMERICA, 1990, 70 (05) : 1061 - 1080
  • [36] INCREASED SURVIVAL FOLLOWING ADJUVANT RADIATION-THERAPY IN OVARIAN CARCINOMA STAGE-I, STAGE-II AND ASYMPTOMATIC STAGE-III
    DEMBO, AJ
    BUSH, RS
    BEALE, FA
    BEAN, HA
    PRINGLE, JF
    STURGEON, J
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 325 - 325
  • [37] Effect of Zoledronic Acid on Disease-Free Survival and Overall Survival in Women with Clinic Stage II/III Undergoing Neoadjuvant Chemotherapy for Breast Cancer
    Aft, R.
    Naughton, M.
    Trinkaus, K.
    Weilbaecher, K.
    [J]. CANCER RESEARCH, 2010, 70
  • [38] Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS)
    Melisko, M.
    Lin, A.
    Rugo, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Adjuvant therapy for early stage breast cancer (EBC): distant disease-free survival (DDFS) as a predictor of overall survival (OS)
    Rugo, H.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 199 - 199
  • [40] 2 YEARS OF CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL AS ADJUVANT CHEMOTHERAPY FOR STAGE-II AND STAGE-III BREAST-CARCINOMA
    CACERES, E
    VALDIVIA, S
    COTRINA, M
    LINGAN, M
    LEON, L
    GAMBOA, M
    OLIVARES, L
    MORAN, M
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1988, 39 (03) : 169 - 174
12345